Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11557914,heart rate,"As expected, heart rate increased from baseline (approximately 8-11 beats/min) at > or =8 mg reboxetine daily.",Lack of effect of reboxetine on cardiac repolarization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557914/),[beats] / [min],8-11,2265,DB00234,Reboxetine
,9176997,tmax,After reboxetine administration mean tmax was about 1 h for both enantiomers.,Pharmacokinetics of reboxetine enantiomers in the dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176997/),h,1,16294,DB00234,Reboxetine
,9176997,Cmax,"Cmax and AUC were about 1.5 times higher for the (R,R)- than for the (S,S)-enantiomer, mean values +/- SD being 704 +/- 330 and 427 +/- 175 ng/ml for Cmax and 2,876 +/- 1,354 and 1,998 +/- 848 ng.h/ml for AUC, respectively.",Pharmacokinetics of reboxetine enantiomers in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176997/),[ng] / [ml],704,16295,DB00234,Reboxetine
,9176997,AUC,"Cmax and AUC were about 1.5 times higher for the (R,R)- than for the (S,S)-enantiomer, mean values +/- SD being 704 +/- 330 and 427 +/- 175 ng/ml for Cmax and 2,876 +/- 1,354 and 1,998 +/- 848 ng.h/ml for AUC, respectively.",Pharmacokinetics of reboxetine enantiomers in the dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176997/),[ng] / [ml],427,16296,DB00234,Reboxetine
,9176997,Cmax,"Cmax and AUC were about 1.5 times higher for the (R,R)- than for the (S,S)-enantiomer, mean values +/- SD being 704 +/- 330 and 427 +/- 175 ng/ml for Cmax and 2,876 +/- 1,354 and 1,998 +/- 848 ng.h/ml for AUC, respectively.",Pharmacokinetics of reboxetine enantiomers in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176997/),[ng] / [ml],427,16297,DB00234,Reboxetine
,9176997,AUC,"Cmax and AUC were about 1.5 times higher for the (R,R)- than for the (S,S)-enantiomer, mean values +/- SD being 704 +/- 330 and 427 +/- 175 ng/ml for Cmax and 2,876 +/- 1,354 and 1,998 +/- 848 ng.h/ml for AUC, respectively.",Pharmacokinetics of reboxetine enantiomers in the dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176997/),[h·ng] / [ml],"2,876",16298,DB00234,Reboxetine
,9176997,AUC,"Cmax and AUC were about 1.5 times higher for the (R,R)- than for the (S,S)-enantiomer, mean values +/- SD being 704 +/- 330 and 427 +/- 175 ng/ml for Cmax and 2,876 +/- 1,354 and 1,998 +/- 848 ng.h/ml for AUC, respectively.",Pharmacokinetics of reboxetine enantiomers in the dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176997/),[h·ng] / [ml],"1,998",16299,DB00234,Reboxetine
,9176997,t1/2,"No differences between the (R,R)- and (S,S)-enantiomers were observed in t1/2 (3.9 h).",Pharmacokinetics of reboxetine enantiomers in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176997/),h,3.9,16300,DB00234,Reboxetine
,9176997,Ae,"Total recovery of the two enantiomers in urine was similar, the Ae (0-48 h) being 1.3 +/- 0.7 and 1.1 +/- 0.7% of the enantiomer dose for the (R,R)- and the (S,S)-enantiomers, respectively.",Pharmacokinetics of reboxetine enantiomers in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176997/),%,1.3,16301,DB00234,Reboxetine
,9176997,Ae,"Total recovery of the two enantiomers in urine was similar, the Ae (0-48 h) being 1.3 +/- 0.7 and 1.1 +/- 0.7% of the enantiomer dose for the (R,R)- and the (S,S)-enantiomers, respectively.",Pharmacokinetics of reboxetine enantiomers in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9176997/),%,1.1,16302,DB00234,Reboxetine
,8148996,analysis time,The HPLC analysis time was about 90 min.,Sensitive procedure for the determination of reboxetine enantiomers in human plasma by reversed-phase high-performance liquid chromatography with fluorimetric detection after chiral derivatization with (+)-1-(9-fluorenyl)ethyl chloroformate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148996/),min,90,40409,DB00234,Reboxetine
,10839469,total urinary recovery,Mean total urinary recovery ranged from 4.06 to 6.17%.,Pharmacokinetics of reboxetine in elderly patients with depressive disorders. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839469/),%,4.06 to 6.17,54674,DB00234,Reboxetine
,10839469,AUCtau,"The mean area under the plasma concentration-time curve (AUCtau) and the maximum plasma drug concentration (Cmax) showed considerable variation between patients; at a dosage of 4 mg/day, AUCtau was 1,466-6,866 ngxh/ml and Cmax ranged from 169 to 663 ng/ml.",Pharmacokinetics of reboxetine in elderly patients with depressive disorders. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839469/),[h·ng] / [ml],"1,466-6,866",54675,DB00234,Reboxetine
,10839469,Cmax,"The mean area under the plasma concentration-time curve (AUCtau) and the maximum plasma drug concentration (Cmax) showed considerable variation between patients; at a dosage of 4 mg/day, AUCtau was 1,466-6,866 ngxh/ml and Cmax ranged from 169 to 663 ng/ml.",Pharmacokinetics of reboxetine in elderly patients with depressive disorders. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839469/),[ng] / [ml],169 to 663,54676,DB00234,Reboxetine
,16699799,M/P,"The mean (95% CI) M/P was 0.06 (0.03, 0.09).","Transfer of reboxetine into breastmilk, its plasma concentrations and lack of adverse effects in the breastfed infant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699799/),,0.06,55377,DB00234,Reboxetine
,16699799,Absolute infant dose,"Absolute infant dose was 1.7 (0.7, 2.4) microg/kg/day for reboxetine while the relative infant dose was 2.0% (1.3, 2.7%).","Transfer of reboxetine into breastmilk, its plasma concentrations and lack of adverse effects in the breastfed infant. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699799/),[μg] / [d·kg],1.7,55378,DB00234,Reboxetine
,25522383,plasma EC50,"TD-9855 engaged norepinephrine transporters (NET) and serotonin transporters (SERT) in rat spinal cord, with a plasma EC50 of 11.7 ng/mL and 50.8 ng/mL, respectively, consistent with modest selectivity for NET in vivo.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],11.7,55633,DB00234,Reboxetine
,25522383,plasma EC50,"TD-9855 engaged norepinephrine transporters (NET) and serotonin transporters (SERT) in rat spinal cord, with a plasma EC50 of 11.7 ng/mL and 50.8 ng/mL, respectively, consistent with modest selectivity for NET in vivo.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],50.8,55634,DB00234,Reboxetine
,25522383,plasma EC50,"Accounting for species differences in protein binding, the projected human NET and SERT plasma EC50 values were 5.5 ng/mL and 23.9 ng/mL, respectively.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],5.5,55635,DB00234,Reboxetine
,25522383,plasma EC50,"Accounting for species differences in protein binding, the projected human NET and SERT plasma EC50 values were 5.5 ng/mL and 23.9 ng/mL, respectively.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],23.9,55636,DB00234,Reboxetine
,25522383,half-life,The long pharmacokinetic half-life (30-40 h) of TD-9855 allowed for sequential assessment of SERT and NET occupancy in the same subject.,"Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),h,30-40,55637,DB00234,Reboxetine
,25522383,plasma EC50,"The plasma EC50 for NET was estimated to be 1.21 ng/mL, and at doses of greater than 4 mg the projected steady-state NET occupancy is high (>75%).","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),[ng] / [ml],1.21,55638,DB00234,Reboxetine
,25522383,occupancy,"After a single oral dose of 20mg, SERT occupancy was 25 (±8)% at a plasma level of 6.35 ng/mL.","Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25522383/),%,25,55639,DB00234,Reboxetine
,20006083,flow rate,"The derivatized plasma samples were injected into the HPLC system where an on-line sample clean up was achieved on the pre-treatment column (Co-sense Shim-pack MAYI-ODS) with a washing mobile phase (acetonitrile:2% acetic acid; 40:60, v/v) at a flow rate of 5mLmin(-1) for 1min.",A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006083/),1/[mlmin],5,59116,DB00234,Reboxetine
,20006083,flow rate,"After an automated on-line column switching to the analytical Hypersil phenyl 120A column (250mmx4.6mm, 5microm), the separation of the derivatized RBX and PXT was performed using a mobile phase consisting of sodium acetate buffer (pH 3.5):tetrahydrofuran:acetonitrile (55:35:10, v/v/v) at a flow rate of 2.0mLmin(-1).",A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006083/),1/[mlmin],2.0,59117,DB00234,Reboxetine
,20006083,recovery,"The accuracy of the method proved as the mean recovery values were 100.11+/-2.24% and 100.99+/-2.98% for the intra- and inter-day assay runs, respectively.",A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006083/),%,100.11,59118,DB00234,Reboxetine
,20006083,recovery,"The accuracy of the method proved as the mean recovery values were 100.11+/-2.24% and 100.99+/-2.98% for the intra- and inter-day assay runs, respectively.",A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006083/),%,100.99,59119,DB00234,Reboxetine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,21.5,59195,DB00234,Reboxetine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,18.9,59196,DB00234,Reboxetine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,14.8,59197,DB00234,Reboxetine
,10546921,terminal half-life,Mean terminal half-life after administration of ketoconazole (21.5 hours and 18.9 hours) was significantly longer than after reboxetine alone (14.8 hours and 14.4 hours; P < or = .005).,Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),h,14.4,59198,DB00234,Reboxetine
,10546921,AUC ratio,"The AUC ratio for R,R(-)-reboxetine to S,S(+)-reboxetine was reduced by ketoconazole administration (2.76 after ketoconazole versus 2.39; P < .003).",Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),,2.76,59199,DB00234,Reboxetine
,10546921,AUC ratio,"The AUC ratio for R,R(-)-reboxetine to S,S(+)-reboxetine was reduced by ketoconazole administration (2.76 after ketoconazole versus 2.39; P < .003).",Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546921/),,2.39,59200,DB00234,Reboxetine
,19058944,total method cycle time,The total method cycle time was 23 min.,"Sensitive quantitation of reboxetine enantiomers in rat plasma and brain, using an optimised reverse phase chiral LC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19058944/),min,23,69381,DB00234,Reboxetine
,8894119,accumulation ratio,"The accumulation ratio, based on repeated-dose/single-dose ratios of Cmax, AUC(0-12 h), and C(12 h) was approximately two.",Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894119/),,two,75976,DB00234,Reboxetine
,10440792,C(max),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[ng] / [ml],38.3,96204,DB00234,Reboxetine
,10440792,C(max),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[ng] / [ml],76. 6,96205,DB00234,Reboxetine
,10440792,C(max),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[ng] / [ml],99.8,96206,DB00234,Reboxetine
,10440792,AUC(infinity),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[h·ng] / [ml],605.8,96207,DB00234,Reboxetine
,10440792,AUC(infinity),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[h·ng] / [ml],1288. 3,96208,DB00234,Reboxetine
,10440792,AUC(infinity),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[h·ng] / [ml],1780.7,96209,DB00234,Reboxetine
,10440792,C(max),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[ng] / [ml],15.2,96210,DB00234,Reboxetine
,10440792,C(max),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[ng] / [ml],34.6,96211,DB00234,Reboxetine
,10440792,C(max),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[ng] / [ml],43.1,96212,DB00234,Reboxetine
,10440792,AUC(infinity),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[h·ng] / [ml],247.0,96213,DB00234,Reboxetine
,10440792,AUC(infinity),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[h·ng] / [ml],529.1,96214,DB00234,Reboxetine
,10440792,AUC(infinity),"C(max) and AUC were more than double for FCE 22071 (C(max): 38.3+/-13.5, 76. 6+/-26.3, 99.8+/-24.1 ng/mL and AUC(infinity): 605.8+/-233.2, 1288. 3+/-796.4, 1780.7+/-669.3 ng. h/mL for 1.5, 3, 4.5 mg, respectively) than for FCE 21684 (C(max): 15.2+/-5.3, 34.6+/-14.0, 43.1+/-12.3 ng/mL and AUC(infinity): 247.0+/-103.9, 529.1+/-278.4, 773.0+/-355.3 ng. h/mL), whatever the administered dose.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),[h·ng] / [ml],773.0,96215,DB00234,Reboxetine
,10440792,half-lives,"The half-lives of the enantiomers were similar (FCE 22071: 13.1, 11.0, 12.6 h and FCE 21684: 12.8, 11.2, 12.2 h after 1.5, 3, 4.5 mg, respectively) and not substantially affected by the dose level.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),h,13.1,96216,DB00234,Reboxetine
,10440792,half-lives,"The half-lives of the enantiomers were similar (FCE 22071: 13.1, 11.0, 12.6 h and FCE 21684: 12.8, 11.2, 12.2 h after 1.5, 3, 4.5 mg, respectively) and not substantially affected by the dose level.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),h,11.0,96217,DB00234,Reboxetine
,10440792,half-lives,"The half-lives of the enantiomers were similar (FCE 22071: 13.1, 11.0, 12.6 h and FCE 21684: 12.8, 11.2, 12.2 h after 1.5, 3, 4.5 mg, respectively) and not substantially affected by the dose level.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),h,12.6,96218,DB00234,Reboxetine
,10440792,half-lives,"The half-lives of the enantiomers were similar (FCE 22071: 13.1, 11.0, 12.6 h and FCE 21684: 12.8, 11.2, 12.2 h after 1.5, 3, 4.5 mg, respectively) and not substantially affected by the dose level.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),h,12.8,96219,DB00234,Reboxetine
,10440792,half-lives,"The half-lives of the enantiomers were similar (FCE 22071: 13.1, 11.0, 12.6 h and FCE 21684: 12.8, 11.2, 12.2 h after 1.5, 3, 4.5 mg, respectively) and not substantially affected by the dose level.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),h,11.2,96220,DB00234,Reboxetine
,10440792,half-lives,"The half-lives of the enantiomers were similar (FCE 22071: 13.1, 11.0, 12.6 h and FCE 21684: 12.8, 11.2, 12.2 h after 1.5, 3, 4.5 mg, respectively) and not substantially affected by the dose level.",Dose proportionality of reboxetine enantiomers in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440792/),h,12.2,96221,DB00234,Reboxetine
,10798303,limit of,The limit of quantification was about 15 ng/ml at 273 nm and about 4 ng/ml at 226 nm.,Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10798303/),ng,4,97408,DB00234,Reboxetine
>,10798303,recovery rates,The day-to-day relative standard deviation ranged between 2.7 and 6.7% with recovery rates > or = 90%.,Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10798303/),%,90,97409,DB00234,Reboxetine
,12973468,terminal elimination half-life,Absorption is rapid and the terminal elimination half-life (13 h) allows twice-daily administration.,"Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12973468/),h,13,104744,DB00234,Reboxetine
,20063149,total run time,Derivatives were then separated on a gas chromatograph coupled with a triple-quadrupole mass spectrometer operating in negative selected reaction monitoring mode for a total run time of 5 min.,"Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063149/),min,5,147690,DB00234,Reboxetine
,20063149,limit of detection,"Despite the small sampling volume, the limit of detection was estimated at 20 pg mL(-1) for all the analytes.","Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063149/),[pg] / [ml],20,147691,DB00234,Reboxetine
,11192474,half-life,"The plasma concentration-time profile following oral administration is best described by a 1-compartment model, and the mean half-life (approximately 12 hours) is consistent with the recommendation to administer the drug twice daily.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),h,12,158838,DB00234,Reboxetine
,11192474,absolute bioavailability,"The absolute bioavailability is 94.5%, and maximal concentrations are generally achieved within 2 to 4 hours.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),%,94.5,158839,DB00234,Reboxetine
,11401003,"S,","Mean S,S(+) reboxetine CLPO for blacks was significantly greater, compared to Asians and Caucasians (154+/-82 ml/min, 101+/-19 ml/min and 101+/-18 ml/min, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[ml] / [min],154,166641,DB00234,Reboxetine
,11401003,CLPO,"Mean S,S(+) reboxetine CLPO for blacks was significantly greater, compared to Asians and Caucasians (154+/-82 ml/min, 101+/-19 ml/min and 101+/-18 ml/min, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[ml] / [min],154,166642,DB00234,Reboxetine
,11401003,CLPO,"Mean S,S(+) reboxetine CLPO for blacks was significantly greater, compared to Asians and Caucasians (154+/-82 ml/min, 101+/-19 ml/min and 101+/-18 ml/min, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[ml] / [min],101,166643,DB00234,Reboxetine
,11401003,CLPO,"Mean S,S(+) reboxetine CLPO for blacks was significantly greater, compared to Asians and Caucasians (154+/-82 ml/min, 101+/-19 ml/min and 101+/-18 ml/min, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[ml] / [min],101,166644,DB00234,Reboxetine
,11401003,S,"Mean S,S(+) reboxetine free fractions (fu) were significantly greater for Asians and blacks, compared to Caucasians (3.04+/-1.28%, 2.89+/-0.69%, and 1.99+/-0.58%, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),%,3.04,166645,DB00234,Reboxetine
,11401003,free fractions (fu),"Mean S,S(+) reboxetine free fractions (fu) were significantly greater for Asians and blacks, compared to Caucasians (3.04+/-1.28%, 2.89+/-0.69%, and 1.99+/-0.58%, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),%,2.89,166646,DB00234,Reboxetine
,11401003,free fractions (fu),"Mean S,S(+) reboxetine free fractions (fu) were significantly greater for Asians and blacks, compared to Caucasians (3.04+/-1.28%, 2.89+/-0.69%, and 1.99+/-0.58%, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),%,1.99,166647,DB00234,Reboxetine
,11401003,unbound clearance (CLu),"S,S(+) Reboxetine unbound clearance (CLu) was significantly less for Asians, compared to blacks and Caucasians (3742+/-1468 ml/min, 5187+/-2027 ml/min, and 5294+/-1163 ml/min, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[ml] / [min],3742,166648,DB00234,Reboxetine
,11401003,unbound clearance (CLu),"S,S(+) Reboxetine unbound clearance (CLu) was significantly less for Asians, compared to blacks and Caucasians (3742+/-1468 ml/min, 5187+/-2027 ml/min, and 5294+/-1163 ml/min, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[ml] / [min],5187,166649,DB00234,Reboxetine
,11401003,unbound clearance (CLu),"S,S(+) Reboxetine unbound clearance (CLu) was significantly less for Asians, compared to blacks and Caucasians (3742+/-1468 ml/min, 5187+/-2027 ml/min, and 5294+/-1163 ml/min, respectively).",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[ml] / [min],5294,166650,DB00234,Reboxetine
,11401003,unbound AUC (AUCu),"S,S(+) Reboxetine mean unbound AUC (AUCu) in these groups were 20.2+/-7.1 ng.h/ml, 14.6+/-5.1 ng.h/ml, and 13.2+/-3.2 ng.h/ml, respectively.",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[h·ng] / [ml],20.2,166651,DB00234,Reboxetine
,11401003,unbound AUC (AUCu),"S,S(+) Reboxetine mean unbound AUC (AUCu) in these groups were 20.2+/-7.1 ng.h/ml, 14.6+/-5.1 ng.h/ml, and 13.2+/-3.2 ng.h/ml, respectively.",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[h·ng] / [ml],14.6,166652,DB00234,Reboxetine
,11401003,unbound AUC (AUCu),"S,S(+) Reboxetine mean unbound AUC (AUCu) in these groups were 20.2+/-7.1 ng.h/ml, 14.6+/-5.1 ng.h/ml, and 13.2+/-3.2 ng.h/ml, respectively.",Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11401003/),[h·ng] / [ml],13.2,166653,DB00234,Reboxetine
,29079874,t 1/2,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,67,216604,DB00234,Reboxetine
,29079874,t max,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,5,216605,DB00234,Reboxetine
,29079874,volume of distribution (V d/F,Large volume of distribution (V d/F = 102 L/kg) indicated its penetration into peripheral compartments.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],102,216606,DB00234,Reboxetine
,29079874,C max,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,60,216607,DB00234,Reboxetine
,29079874,volume of distribution (V d/F,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],32.2,216608,DB00234,Reboxetine
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,19,216609,DB00234,Reboxetine
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,7.5,216610,DB00234,Reboxetine
,29079874,IC 50,"EMD386088 did not influence on CYP3A4 activity, and it has been classified as a very weak CYP2D6 inhibitor (IC 50 = 2.25 μM).","Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),μM,2.25,216611,DB00234,Reboxetine
,7579027,tmax,Plasma levels indicated a rapid absorption (tmax approximately equal to 2 h) and an elimination half-life of about 13 h.,"Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579027/),h,2,225206,DB00234,Reboxetine
,7579027,elimination half-life,Plasma levels indicated a rapid absorption (tmax approximately equal to 2 h) and an elimination half-life of about 13 h.,"Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579027/),h,13,225207,DB00234,Reboxetine
,7579027,CL/F,"Clearance and volume of distribution were modest (ratios to bioavailability: CL/F approximately equal to 29 mL min-1; Vz/F approximately equal to 32 L); urinary excretion was approximately 9% of dose, corresponding to a renal clearance of only 3 mL min-1 (a value consistent with the rate of glomerular filtration of unbound drug).","Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579027/),[ml] / [min],29,225208,DB00234,Reboxetine
,7579027,Vz/F,"Clearance and volume of distribution were modest (ratios to bioavailability: CL/F approximately equal to 29 mL min-1; Vz/F approximately equal to 32 L); urinary excretion was approximately 9% of dose, corresponding to a renal clearance of only 3 mL min-1 (a value consistent with the rate of glomerular filtration of unbound drug).","Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579027/),l,32,225209,DB00234,Reboxetine
,7579027,urinary excretion,"Clearance and volume of distribution were modest (ratios to bioavailability: CL/F approximately equal to 29 mL min-1; Vz/F approximately equal to 32 L); urinary excretion was approximately 9% of dose, corresponding to a renal clearance of only 3 mL min-1 (a value consistent with the rate of glomerular filtration of unbound drug).","Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579027/),%,9,225210,DB00234,Reboxetine
,7579027,renal clearance,"Clearance and volume of distribution were modest (ratios to bioavailability: CL/F approximately equal to 29 mL min-1; Vz/F approximately equal to 32 L); urinary excretion was approximately 9% of dose, corresponding to a renal clearance of only 3 mL min-1 (a value consistent with the rate of glomerular filtration of unbound drug).","Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579027/),[ml] / [min],3,225211,DB00234,Reboxetine
,7579027,Cmax,"In vitro, binding to plasma proteins, estimated from radioactivity levels following dialysis of 14C-labelled reboxetine, appeared to be dominated by alpha 1-acid glycoprotein without marked saturation up to plasma concentrations of over 500 ng mL-1 (2.8-3.1% unbound with human plasma from three additional volunteers; 1.8-2.0% for 2 gL-1 orosomucoid alpha 1-acid glycoprotein, and 46.4-47.4% for 40 g L-1 albumin), whilst the mean Cmax in the current study was much lower (164 ng mL-1 after a 5mg dose).","Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579027/),[ng] / [ml],164,225212,DB00234,Reboxetine
,10086838,absolute bioavailability,"The absolute bioavailability was 0.919 and 1.02 for R,R(-) reboxetine and S,S(+) reboxetine, respectively.",Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086838/),,0.919,238474,DB00234,Reboxetine
,10086838,absolute bioavailability,"The absolute bioavailability was 0.919 and 1.02 for R,R(-) reboxetine and S,S(+) reboxetine, respectively.",Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10086838/),,1.02,238475,DB00234,Reboxetine
,11420889,Cmax,"Cmax in the elderly was 271 +/- 86 ng/ml, compared with 111 +/- 28 ng/ml in the young subjects after a single 4-mg dose, although in both groups Cmax was observed after 2 h.","Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),[ng] / [ml],271,240422,DB00234,Reboxetine
,11420889,Cmax,"Cmax in the elderly was 271 +/- 86 ng/ml, compared with 111 +/- 28 ng/ml in the young subjects after a single 4-mg dose, although in both groups Cmax was observed after 2 h.","Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),[ng] / [ml],111,240423,DB00234,Reboxetine
,11420889,AUC infinity,The AUC infinity was nearly four times that in the younger subjects (8345 +/- 3107 ng.h/ml vs. 2106 +/- 881 ng.h/ml) and the t1/2 was twice as long (24 +/- 6 h vs. 12 +/- 3 h).,"Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),[h·ng] / [ml],8345,240424,DB00234,Reboxetine
,11420889,AUC infinity,The AUC infinity was nearly four times that in the younger subjects (8345 +/- 3107 ng.h/ml vs. 2106 +/- 881 ng.h/ml) and the t1/2 was twice as long (24 +/- 6 h vs. 12 +/- 3 h).,"Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),[h·ng] / [ml],2106,240425,DB00234,Reboxetine
,11420889,t1/2,The AUC infinity was nearly four times that in the younger subjects (8345 +/- 3107 ng.h/ml vs. 2106 +/- 881 ng.h/ml) and the t1/2 was twice as long (24 +/- 6 h vs. 12 +/- 3 h).,"Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),h,24,240426,DB00234,Reboxetine
,11420889,t1/2,The AUC infinity was nearly four times that in the younger subjects (8345 +/- 3107 ng.h/ml vs. 2106 +/- 881 ng.h/ml) and the t1/2 was twice as long (24 +/- 6 h vs. 12 +/- 3 h).,"Pharmacokinetics of reboxetine in healthy, elderly volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11420889/),h,12,240427,DB00234,Reboxetine
